-Overall The clinical landscape of melanoma is evolving rapidly, however, a significant fraction of individuals fail to respond to frontline therapy, and another significant fraction of melanoma patients develop resistance. In order to improve the response to frontline therapies, we have previously focused on inhibiting survival pathways, including autophagy, senescence and proteostasis. In the new funding cycle, we extend this focustowardtargetingthemelanomamicroenvironment. Targeted therapies designed to inhibit tumor-intrinsic signaling do not contemplate the influences of the microenvironment, and the recent success of immunotherapy is a reminder of how important the consideration of the microenvironment is. Our data are revealing that the normal aging of stromal cells creates a microenvironment that promotes the activation of signaling pathways that circumvent those targeted by therapies such as vemurafenib, making the one gene, one drug approach less likely to be successful. Additionally, the crosstalkbetweenstromal and immunecells in the tumor microenvironment is vastly underexplored. We believe that genetic drivers in the tumor cell, or specific checkpoints on immune cells cannot be effectively targeted, without the consideration of the crosstalk between thosecellpopulationsandothercellsinthemicroenvironment. TheProgram consistsoffour well-integratedprojects, fromateam thathas workedextremely welltogether over the last five years, publishing numerous high-impact collaborative papers. The evolution of this P01 into its new form is truly a reflection of these concerted efforts, evolving from targeting cell fate, to a realization that cell fate can be differentially affected by its microenvironment. The four Projects are designed in order to achieve a fully coordinated understanding of how multiple factors (but with a focus on aging) in the tumor microenvironment contribute to therapy resistance. The alteration of lipid profiles in stromal, immune and tumor cells isemerging asa keydriverof resistance. TheProjects will worktogether to understand the impact of lipid production, accumulation, uptake, metabolism and catabolism in tumor cells. Using the novel compounds developed within the current funding cycle of the grant, we will target tumor/TMEcrosstalk,andexplorenovelwaysinwhichtodisruptit.
-Overall This program project is a renewal from a highly productive team of investigators, which produced 107 publications, >70% of which are collaborations among the team. Overall, our findings in the 2013-2018 cycle have led to a natural evolution of our studies, where we found that the aged microenvironment is a key contributortotherapyresistance,andthatlipidmetabolismisacriticalregulatorofbothtumorcellandimmune cell response, resulting in forms of cell death such as ferroptosis. Using the tools we have developed in the current funding cycle (dimeric quinacrines, HSP70 inhibitors) and our new understanding of the role of the tumor microenvironment in therapy resistance, this Program focuseson how toovercome resistance and lack ofresponsetotherapybytargetingnotjustthetumor,butalsothemicroenvironment.
Showing the most recent 10 out of 144 publications
